The FDA’s approval was supported by data from analytical, preclinical, and clinical research showing that Hyrimoz matched the reference product’s safety, efficacy, and quality.
Data from the CDC show that the prevalence of anxiety and depression is higher among adults with arthritis compared with the general population.
Anti-TNF-α therapy has a beneficial effect on the metabolism of proteoglycans and glycosaminoglycans tissue in women with rheumatoid arthritis.
Patients with obesity and rheumatoid arthritis experienced worse clinical and ultrasonographic outcomes.
Sexual dysfunction may be common in women with rheumatoid arthritis and affect all subdomains of sexual function.
Survey data suggest a high level of satisfaction with intravenous administration of biologic therapy among patients with rheumatoid arthritis.
Study results support the recommended use of bDMARDs in combination with csDMARDs in patients with RA.
Higher remission rates and better quality of life were achieved in patients with rheumatoid arthritis who received a treat-to-target strategy.
Centralized pain pathways may coexist with more established peripheral inflammation-driven pathways in some patients with RA.
Given the substantial overlap with RA, emerging theories suggest that undifferentiated arthritis represents a unique window of opportunity to intervene in the pathology of RA before it becomes established.